Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0033774 (pruritus)
 14,546 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The levels of serum IgG complement-fixing immune complexes were studied in 20 children with atopic eczema and in 10 children with allergic rhinitis as control subjects with the use of a Raji cell assay. Immune-complex levels were strikingly elevated in those with eczema, 50 +/- 10 SE micrograms/ml, compared to control subjects 11 +/- 9 micrograms/ml (p less than 0.0047), the latter falling within the range for nonallergic subjects. Levels tended to be higher in those subjects with more severe eczema, but there was no statistically significant correlation, nor were levels correlated with serum IgE. Sucrose-density gradient analysis demonstrated the immune complexes to be present in two peaks, 8 to 10S and 21S or higher. High-molecular-weight IgG immune complexes that are complement-fixing may promote the characteristic pruritus of eczema by formation of anaphylactic complement fragments and the release of inflammatory substances from cutaneous mast cells, as well as contributing to the impaired cell-mediated immunity associated with the disease.
 ...
PMID:Elevated IgG immune complexes in children with atopic eczema. 650 40

The efficacy of once a day applications of 0.05% diflorasone diacetate ointment and twice a day applications of 0.1% betamethasone valerate ointment was compared in 70 patients with eczematous dermatitis. Altogether 32 patients completed the 3-week study. Fourteen patients in the diflorasone group and 6 on betamethasone left the study earlier because of total (100%) improvement of lesions. Eight patients left because of unsatisfactory progress and 6 because of personal reasons. There were only two noticeable differences observed between treatment groups. At Week 2, the diflorasone diacetate group improved significantly more than the betamethasone valerate group with respect to pruritus. At Week 3, this difference in the improvement of pruritus was marginally significant in favour of diflorasone diacetate. Excluding the complications due to a secondary infection, no adverse reactions were recorded in the diflorasone diacetate-treated patients; 1 betamethasone valerate-treated patient developed telangiectasia. The once a day applications of diflorasone diacetate not only proved to be slightly more efficacious than the twice a day applications of betamethasone valerate, but also provided the advantages of patient convenience and compliance.
 ...
PMID:Comparative efficacy of once a day diflorasone diacetate and twice a day betamethasone valerate ointment applications in eczematous dermatitis. 651 15

The psychosomatic aspects of the pruritus symptom of endogenous eczema patients are presented. The phenomenon of "scratching" is analysed descriptively from observations of the behavior of the patient and his family. Psychotherapeutic approaches as a supplement to the dermatological therapy of endogenous eczema are described.
 ...
PMID:[The pruritus of endogenous eczema patients (author's transl)]. 678 64

A 2-week, double-blind clinical trial was conducted to compare the efficacy and cosmetic acceptability of amcinonide cream 0.1 percent and halcinonide cream 0.1 percent in the treatment of 29 patients with eczematous dermatitis. The dermatologic status of each patient was rated by improvement in clinical signs and symptoms, by the investigator's overall evaluation, and by two patient evaluations. Both medications produced statistically significant and equivalent improvement by Week 2. However, amcinonide was significantly favored in the efficacy evaluation of relief from burning pain at Week 2 and in patient acceptability evaluations in regard to the absence of burning, stinging, and itching on application. The role of propylene glycol in the formulation of the halcinonide cream as a contributing cause of irritation is noted.
 ...
PMID:A controlled comparison of amcinonide cream 0.1 percent and halcinonide cream 0.1 percent in the treatment of eczematous dermatitis. 703 Jun 45

The aim of this study was to measure the effect of in-patient management on the quality of life of adult dermatology patients, and to identify the diagnostic categories which show the greatest improvement. Over a 6-month period, all 230 patients admitted to the dermatology ward of the University Hospital of Wales were invited to complete a Dermatology Life Quality Index (DLQI) questionnaire on admission, and again 4 weeks after discharge. Two hundred and seventeen (93%) of these patients entered the study, and 181 (83.4%) returned both questionnaires. The mean DLQI on admission was 13.2 (standard deviation [SD] 7.6; n = 181), and 4 weeks after discharge it was 7.7 (SD 6.8; P < 0.001). Seventy-three per cent of the 181 patients showed improvement, 5.5% remained unchanged, and 21.5% worsened. Patients with psoriasis improved from 13.7 (SD 6.5) to 6.7 (SD 5.6; n = 63; P < 0.001), and those with eczema improved from 16.2 (SD 6.3) to 9.6 (SD 7.6; n = 56; P < 0.001). Patients with pruritus showed little improvement, as did those admitted for liver biopsy. Patients with psoriasis and severe eczema showed, overall, a significant decrease in impairment of life quality following in-patient treatment. Severe eczema has a greater adverse impact on the quality of life than severe psoriasis. The parameters for which most improvement was seen were those which were of most concern to the patients, i.e. their symptoms (score after discharge = 1.2; DS 0.9; P < 0.001) and their embarrassment (0.9; SD 1.0; P < 0.001).
 ...
PMID:Dermatology in-patient management greatly improves life quality. 757 87

Sensitization and immune disorders from metallic prostheses are very unusual although most of them were metal-metal structures (nickel, cobalt or chromium alloys) during decades. Recent technical modifications; the use of new metal (titan-vanadium), of aluminum or ceramic prostheses eliminate these side effects; The clinical diseases may be regional (eczema, dermatitis, vascularitis) or general (diffuse dermatitis, itching). Some very rare systemic diseases have been described but their relation with the prosthesis is often uncertain. The positive patch tests are good indicators of the sensitization but their high prevalence of metal sensitization in the normal population excludes a safe diagnosis. The best demonstration remains the complete recovery of the disease after removal of the prosthesis.
 ...
PMID:[Incidents and side effects of metallic orthopedic and odontologic prostheses]. 764 98

A randomized controlled trial compared the effectiveness of 4 group treatments for atopic dermatitis, a chronic skin disorder characterized by severe itching and eczema: dermatological educational program (DE), autogenic training as a form of relaxation therapy (AT), cognitive-behavioral treatment (BT), and the combined DE and BT treatments (DEBT). BT comprised relaxation, self-control of scratching, and stress management. Group treatments were also compared with standard medical care (SMC). Assessments at 1-year follow-up showed that the psychological treatments (AT, BT, and DEBT) led to significantly larger improvement in skin condition than intensive (DE) or standard (SMC) dermatological treatment, accompanied by significant reductions in topical steroids used. The results corroborate preliminary reports that psychological interventions are useful adjuncts to dermatological treatment in atopic dermatitis.
 ...
PMID:Treatment of atopic dermatitis: a comparison of psychological and dermatological approaches to relapse prevention. 767 40

In 1979 the first case of contact urticaria to rubber gloves was reported in a patient with a positive skin prick test to latex. The use of articles containing rubber is widespread and this can explain the increasing frequency of allergic reactions to natural rubber latex. The symptoms may be localized like contact urticaria or systemic like angioedema, generalized urticaria or anaphylactic shock. In this study we have considered 12 patients who presented clinical manifestations after direct contact with objects containing rubber. Three patients had eczema and pruritus after the use of household gloves, 4 subjects had lips and tongue oedema following the contact with rubber tube during a dental treatment, 5 patients suffered from urticaria and pruritus during the use of surgical gloves. Generalized angioedema was also present in 4 out of 12 patients. All the patients had positive Skin prick test and Rast to latex. Three out of 12 patients were atopic. Our study confirms the increasing frequency of immediate hypersensitivity reactions to latex. This phenomenon must be taken into account especially before surgery, since severe clinical manifestations such as anaphylactic shock may occur.
 ...
PMID:[Latex allergy]. 775 80

The efficacy and safety of gamma-linolenic acid in the treatment of atopic dermatitis was evaluated. The children (mean age, 11.4 months) with atopic dermatitis (mean duration, 8.56 months) were openly treated with 3 g/day gamma-linolenic acid, for 28 days. Clinical evaluations were carried out every 7 days, and parents were asked to keep a diary, recording details of symptoms of eczema every day. Blood chemistry and immunological tests were done before and after treatment. None of the children showed complete recovery of symptoms. A gradual improvement in erythema, excoriations and lichenification was seen; significant differences were shown for itching (P < 0.01), and the use of antihistamines (P < 0.01). A significant rise in the percentage of circulating CD8 was found. No side-effects were recorded. Dietetic and pharmacological approaches are the basis of the treatment of atopic dermatitis and gamma-linolenic acid appears to be a safe and efficient additional therapy for infants and young children.
 ...
PMID:The efficacy and safety of gamma-linolenic acid in the treatment of infantile atopic dermatitis. 791 May 70

We have studied two reducing-dose regimens intended to minimize toxicity of cyclosporin A (CyA) while maintaining its capacity to control atopic eczema following induction of remission. Twenty-four patients with severe chronic atopic eczema were first treated in a double-blind randomized placebo-controlled cross-over study of CyA (5 mg/kg/day). All 19 who completed the study showed the expected highly significant improvements, compared with placebo, in area involved, erythema, excoriation, lichenification, itch and requirement for topical steroid. In 17 of the 19 patients, control was re-established with CyA 5 mg/kg/day, and they were then re-randomized to stepwise reduction at 2-week intervals in either (i) the dose of CyA given daily, or (ii) the frequency with which the 5 mg/kg dose was given. Fifteen patients (seven continuous reducing dose, eight intermittent fixed dose) completed the planned reduction to either 1 mg/kg/day or 5 mg/kg every fifth day. In both groups the response was sustained despite dose reduction, although control was less good at a continuous dose of 1 mg/kg. Intermittent treatment was as good as or better than continuous reducing dosage in this study, and in both groups there was further deterioration after the drug was stopped. The findings suggest that the dose of CyA required to control atopic eczema is less than that required to achieve remission, and that the therapeutic index can be further improved by alternative dosing strategies. This offers a new approach to maintenance treatment of eczema and other chronic refractory dermatoses.
 ...
PMID:Maintenance treatment with cyclosporin in atopic eczema. 814 81


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>